Riskpilot← Back to searchSign inGet full accessGyn Carstensen AB
ABActiveOrg 5569324444Polhemsgatan 4 5trMedical specialists activities · NACE 8622Est. 20135-9 employees
Revenue 2025
SEK 5,9M
+11% vs 2024
EBITDA margin
17.8%
+24% vs 2024
Equity ratio
87.5%
Financial strength
Net profit 2025
SEK 822K
+33% vs 2024
| Revenue | SEK 5,9M | +11% |
| EBITDA | SEK 1,1M | +24% |
| Net profit | SEK 822K | +33% |
| Total assets | SEK 3,8M | -11% |
| Equity | SEK 3,3M | -5% |
| Employees | — | — |
Legal name
Gyn Carstensen AB
Org number
5569324444
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
21 maj 2013
Share capital
SEK 50 000
Employees
5-9
VAT registered
No
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget ska bedriva läkarvård samt konsult- och utbildningsverksamhet inom området medicinsk och farmaceutisk forskning och utveckling, litterär verksamhet och handel med värdepapper och fastigheter ävensom idka därmed förenlig verksamhet.
Address
Polhemsgatan 4 5tr
Phone
+46737776988
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 4 070 | 5 427 | 5 661 | 5 354 | 5 928 |
| Staff expenses | — | — | −2 580 | −2 560 | −2 582 |
| EBITDA | 418 | 950 | 1 499 | 854 | 1 057 |
| Depreciation & amort. | −128 | −81 | −49 | −22 | −64 |
| EBIT | 290 | 869 | 1 450 | 832 | 993 |
| Net financials | 188 | −53 | 1 | 20 | 26 |
| Profit before tax | 478 | 842 | 1 451 | 782 | 1 034 |
| Tax | −103 | −174 | −299 | −162 | −212 |
| Net profit | 375 | 668 | 1 152 | 620 | 822 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 611 | 4 010 | 4 356 | 4 243 | 3 763 |
| Equity | 3 229 | 3 497 | 3 849 | 3 469 | 3 291 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 382 | 513 | 507 | 704 | 416 |
| Total debt | 382 | 513 | 507 | 704 | 416 |
EBITDA margin
17.8%
This company
15.8%
Market median
+13% vs market
20212025
Equity ratio
87.5%
This company
38.2%
Market median
+129% vs market
20212025
Return on equity
25.0%
This company
18.4%
Market median
+36% vs market
20212025
Net profit margin
13.9%
This company
8.1%
Market median
+72% vs market
20212025
Asset turnover
1.58×
This company
1.12×
Market median
+41% vs market
20212025
Debt / equity
0.14×
This company
0.62×
Market median
+77% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PW Audit | Audit | 2025 |
| Former (1) | ||
| Audit | 2024 – 2025 | |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Gyn Carstensen AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sara Camilla Elisabeth Walgeborg | Audit | 0 companies |
| Patricie Weis | Audit | 0 companies |
| Katajon Nazemian | Board of Directors | 0 companies |
| Bita Nazemian | Deputy Board Member | 0 companies |